Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2011, Article ID 195146, 9 pages
http://dx.doi.org/10.1155/2011/195146
Research Article

Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats

1Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan
2Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan
3CyDex Pharmaceuticals, Inc., Lenexa, KS 66214-1643, USA

Received 29 July 2011; Accepted 19 September 2011

Academic Editor: Roberta Cavalli

Copyright © 2011 Keiko Uehata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Blickle, J. Doucet, T. Krummel, and T. Hannedouche, “Diabetic nephropathy in the elderly,” Diabetes and Metabolism, vol. 33, supplement 1, pp. S40–S55, 2007. View at Google Scholar
  2. B. Patterson, A. V. Fields, and R. P. Shannon, “New insights into myocardial glucose metabolism: surviving under stress,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 424–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Simo, E. Carrasco, M. Garcia-Ramirez, and C. Hernandez, “Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy,” Current Diabetes Reviews, vol. 2, no. 1, pp. 71–98, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. S. Horton, “Can newer therapies delay the progression of type 2 diabetes mellitus?” Endocrine Practice, vol. 14, no. 5, pp. 625–638, 2008. View at Google Scholar · View at Scopus
  5. A. Rolla, “Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety,” American Journal of Medicine, vol. 121, supplement 6, pp. S9–S19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Wang, J. M. Carabino, and C. M. Vergara, “Insulin glargine: a systematic review of a long-acting insulin analogue,” Clinical Therapeutics, vol. 25, no. 6, pp. 1541–1577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Szente and J. Szejtli, “Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development,” Advanced Drug Delivery Reviews, vol. 36, no. 1, pp. 17–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Uekama, F. Hirayama, and T. Irie, “Cyclodextrin drug carrier systems,” Chemical Reviews, vol. 98, no. 5, pp. 2045–2076, 1998. View at Google Scholar · View at Scopus
  9. K. Shiotani, T. Irie, K. Uekama, and Y. Ishimaru, “Cyclodextrin sulfates in parenteral use: protection against gentamicin nephrotoxicity in the rat,” European Journal of Pharmaceutical Sciences, vol. 3, no. 3, pp. 139–151, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. V. J. Stella and R. A. Rajewski, “Cyclodextrins: their future in drug formulation and delivery,” Pharmaceutical Research, vol. 14, no. 5, pp. 556–567, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Uekama, “Design and evaluation of cyclodextrin-based drug formulation,” Chemical and Pharmaceutical Bulletin, vol. 52, no. 8, pp. 900–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Uekama and M. Otagiri, “Cyclodextrins in drug carrier systems,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 3, no. 1, pp. 1–40, 1987. View at Google Scholar · View at Scopus
  13. V. J. Stella and Q. He, “Cyclodextrins,” Toxicologic Pathology, vol. 36, no. 1, pp. 30–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Irie and K. Uekama, “Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation,” Journal of Pharmaceutical Sciences, vol. 86, no. 2, pp. 147–162, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Tokihiro, T. Irie, P. Hirayama, and K. Uekama, “Mass spectroscopic evidence on inhibiting effect of maltosyl-β-cyclodextrin on insulin self-association,” Pharmaceutical Sciences, vol. 2, no. 11, pp. 519–522, 1996. View at Google Scholar · View at Scopus
  16. K. Tokihiro, T. Irie, and K. Uekama, “Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution,” Journal of Pharmaceutical Sciences, vol. 1, pp. 49–53, 1995. View at Google Scholar
  17. K. Tokihiro, T. Irie, and K. Uekama, “Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution,” Chemical and Pharmaceutical Bulletin, vol. 45, no. 3, pp. 525–531, 1997. View at Google Scholar · View at Scopus
  18. K. Tokihiro, H. Arima, S. Tajiri, T. Irie, T. Hirayama, and K. Uekama, “Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether β-cyclodextrin in rats,” Journal of Pharmacy and Pharmacology, vol. 52, no. 8, pp. 911–917, 2000. View at Google Scholar
  19. K. Uehata, T. Anno, K. Hayashida et al., “Effect of sulfobutyl ether-ß-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats,” International Journal of Pharmaceutics. In press.
  20. J. Pitha, L. M. Mallis, D. J. Lamb, T. Irie, and K. Uekama, “Cyclodextrin sulfates: characterization as polydisperse and amorphous mixtures,” Pharmaceutical Research, vol. 8, no. 9, pp. 1151–1154, 1991. View at Google Scholar · View at Scopus
  21. K. Ikeda, K. Uekama, and M. Otagiri, “Inclusion complexes of β-cyclodextrin with antiinflammatory drugs fenamates in aqueous solution,” Chemical and Pharmaceutical Bulletin, vol. 23, no. 1, pp. 201–208, 1975. View at Google Scholar · View at Scopus
  22. M. E. Brewster, M. S. Hora, J. W. Simpkins, and N. Bodor, “Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs,” Pharmaceutical Research, vol. 8, no. 6, pp. 792–795, 1991. View at Google Scholar · View at Scopus
  23. S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, and K. Uekama, “Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor,” Journal of Pharmaceutical Sciences, vol. 95, no. 12, pp. 2722–2729, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Goldman and F. H. Carpenter, “Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives,” Biochemistry, vol. 13, no. 22, pp. 4566–4574, 1974. View at Google Scholar · View at Scopus
  25. J. Brange, L. Andersen, E. D. Laursen, G. Meyn, and E. Rasmussen, “Toward understanding insulin fibrillation,” Journal of Pharmaceutical Sciences, vol. 86, no. 5, pp. 517–525, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Havelund, A. Plum, U. Ribel et al., “The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin,” Pharmaceutical Research, vol. 21, no. 8, pp. 1498–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Kurtzhals, “Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir,” International Journal of Obesity, vol. 28, supplement 2, pp. S23–S28, 2004. View at Google Scholar
  28. R. J. Schilling and A. K. Mitra, “Degradation of insulin by trypsin and α-chymotrypsin,” Pharmaceutical Research, vol. 8, no. 6, pp. 721–727, 1991. View at Google Scholar · View at Scopus
  29. H. K. S. Leiros, B. O. Brandsdal, O. A. Andersen et al., “Trypsin specificity as elucidated by LIE calculations, X-ray structures, and association constant measurements,” Protein Science, vol. 13, no. 4, pp. 1056–1070, 2004. View at Publisher · View at Google Scholar · View at Scopus